TrialRespiratory research2022

Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the  phase 2 PANAMO trial.

Endry H T Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.